- Home
- VERU vs RNXT Comparison
VERU vs RNXT Comparison
Compare VERU & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- RNXT
- Stock Information
- Founded
- VERU 1971
- RNXT 2012
- Country
- VERU United States
- RNXT United States
- Employees
- VERU N/A
- RNXT N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- RNXT Health Care
- Exchange
- VERU Nasdaq
- RNXT Nasdaq
- Market Cap
- VERU 54.6M
- RNXT 44.0M
- IPO Year
- VERU 1990
- RNXT 2021
- Fundamental
- Price
- VERU $3.75
- RNXT $1.12
- Analyst Decision
- VERU Strong Buy
- RNXT Strong Buy
- Analyst Count
- VERU 3
- RNXT 2
- Target Price
- VERU $33.33
- RNXT $7.50
- AVG Volume (30 Days)
- VERU 139.0K
- RNXT 579.1K
- Earning Date
- VERU 12-15-2025
- RNXT 11-13-2025
- Dividend Yield
- VERU N/A
- RNXT N/A
- EPS Growth
- VERU N/A
- RNXT N/A
- EPS
- VERU N/A
- RNXT N/A
- Revenue
- VERU $16,886,419.00
- RNXT $662,000.00
- Revenue This Year
- VERU N/A
- RNXT $2,895.35
- Revenue Next Year
- VERU N/A
- RNXT $313.04
- P/E Ratio
- VERU N/A
- RNXT N/A
- Revenue Growth
- VERU 337.24
- RNXT N/A
- 52 Week Low
- VERU $2.64
- RNXT $0.75
- 52 Week High
- VERU $14.20
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- VERU 47.71
- RNXT 45.33
- Support Level
- VERU $3.61
- RNXT $1.12
- Resistance Level
- VERU $3.99
- RNXT $1.15
- Average True Range (ATR)
- VERU 0.30
- RNXT 0.07
- MACD
- VERU -0.10
- RNXT -0.01
- Stochastic Oscillator
- VERU 14.52
- RNXT 28.00
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.